Upregulation of long non-coding RNA MALAT1 correlates with tumor progression and poor prognosis in clear cell renal cell carcinoma

Abstract

Long noncoding RNAs (lncRNAs) have been investigated as a new class of regulators of cellular processes, such as cell growth, apoptosis, and carcinogenesis. LncRNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has recently been identified to be involved in tumorigenesis of several cancers such as lung cancer, pancreatic cancer, and cervical cancer. However, the role of lncRNA MALAT1 in clear cell renal cell carcinoma (ccRCC) remains unclear. Expression levels of lncRNA MALAT1 in ccRCC tissues and renal cancer cell lines were evaluated by quantitative real-time PCR (qRT-PCR), and its association with overall survival of patients was analyzed by statistical analysis. Small interfering RNA (siRNA) was used to suppress MALAT1 expression in renal cancer cells. In vitro assays were conducted to further explore its role in tumor progression. The expression level of MALAT1 was higher in ccRCC tissues and renal cancer cells compared to adjacent non-tumor tissues and normal human proximal tubule epithelial cells HK-2. The ccRCC patients with higher MALAT1 expression had an advanced clinical features and a shorter overall survival time than those with lower MALAT1 expression. And multivariate analysis showed that the status of MALAT1 expression was an independent predictor of overall survival in ccRCC. Additionally, our data indicated that knockdown expression of MALAT1 decreased renal cancer cell proliferation, migration, and invasion. Our data suggested that lncRNA MALAT1 was a novel molecule involved in ccRCC progression, which provided a potential prognostic biomarker and therapeutic target.

Downregulation of long non-coding RNA TRIM52-AS1 functions as a tumor suppressor in renal cell carcinoma

“…In previous years, due to the successful application of different novel approaches, including genome-wide gene expression screening, genome-wide association studies, region-targeted association assays and conventional linkage screening, designed LncRNA arrays, RIP-RNA sequencing, transgenic expression, and gene knockdown or knockout, the functions of LncRNAs in cancer are being increasingly characterized. Accumulating data show that several identified LncRNAs are crucial in tissue carcinogenesis, invasion and metastasis (11)(12)(13)(14)(15).…”

Long non-coding RNA HOXA transcript at the distal tip as a biomarker for gastric cancer

“…Previously, multiple studies reported that in different types of cancer there was abnormal expression of lncRNA, indicating that the same lncRNA may serve different functions in different types of cancer. For instance, a lncRNA named SPRY4 intronic transcript 1 (SPRY4-IT1) was reported to be overexpressed in melanoma, renal cell carcinoma, esophageal squamous cell carcinoma, breast cancer, bladder cancer and glioma, and associated with poor prognosis and promotion of tumor growth (24)(25)(26)(27)(28)(29). Certain studies also demonstrated that SPRY4-IT1 expression was decreased in non-small-cell lung cancer and gastric cancer, and acted with significant antitumor function in these two types of cancer (30,31).…”

lncRNA uc009yby.1 promotes renal cell proliferation and is associated with poor survival in patients with clear cell renal cell carcinomas

“…Several studies have indicated that lncRNA expression profiles may act as biomarkers for diagnosis of ccRCC; lncRNA MALAT1, for example, was reported to be associated with tumor progression and poor prognosis in ccRCC (9), and lncRNA CADM1-AS1 was associated with poor prognosis in patients with ccRCC. Consistent with these findings, the current data revealed that the expression profiles of uc009yby.1 and ENST00000514034 had high sensitivity and specificity in distinguishing ccRCC from normal tissues.…”

“…For example, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) interacts with enhancer of zeste homolog 2 and microRNA-205 to suppress the E-cadherin expression in RCC cells, suggesting that MALAT1 may offer a novel theranostic marker for RCC (8). An increasing number of studies have also demonstrated that certain lncRNAs are strongly associated with patient survival and early pathological changes in ccRCC (9,10). Recently, a large number of lncRNAs that have aberrant expression in ccRCC were screened via lncRNA microarray in several studies (11)(12)(13); however, the expression of these lncRNAs have not been further confirmed and their functions in ccRCC cells have not been explored.…”